GERN
Geron Corporation
NASDAQ · Healthcare · Biotechnology · US
$1.57
+3.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 204.6M | 183.9M | 77.0M | 237.0K | 596.0K |
| Cost of Revenue | 34.4M | 4.7M | 1.3M | — | — |
| Gross Profit | 170.2M | 179.1M | 75.7M | 237.0K | 596.0K |
| Operating Expenses | |||||
| R&D Expense | 73.9M | 73.7M | 103.7M | 125.0M | 95.5M |
| SG&A Expense | 155.0M | 159.3M | 145.7M | 69.1M | 43.6M |
| General & Admin Expense | 38.9M | — | 145.7M | 69.1M | 43.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (21.2M) | — | — | — | — |
| Total Operating Expenses | 207.6M | 233.0M | 249.5M | 194.2M | 139.1M |
| Cost and Expenses | 242.0M | 237.7M | 250.7M | 194.2M | 139.1M |
| Operating Income (EBIT) | (37.4M) | (53.8M) | (173.7M) | (193.9M) | (138.6M) |
| Non-Operating | |||||
| Interest Income | 14.7M | 18.1M | 19.6M | 18.2M | 2.5M |
| Interest Expense | 30.2M | 32.7M | 18.5M | 8.3M | 6.9M |
| Net Interest Income | (15.5M) | (14.5M) | 1.1M | 9.8M | (4.4M) |
| Other Non-Op Income/Expense | (32.5M) | (31.9M) | (840.0K) | 9.8M | (3.4M) |
| Non-Operating Income (excl Interest) | 5.2M | (710.0K) | (17.7M) | (18.1M) | (3.5M) |
| EBT (Pre-Tax Income) | (69.9M) | (85.8M) | (174.6M) | (184.1M) | (141.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (69.9M) | (85.8M) | (174.6M) | (184.1M) | (141.9M) |
| Earnings from Cont. Ops | (69.9M) | (85.8M) | (174.6M) | (184.1M) | (141.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (69.9M) | (85.8M) | (174.6M) | (184.1M) | (141.9M) |
| Per Share | |||||
| Basic EPS | ($0.10) | ($0.13) | ($0.27) | ($0.32) | ($0.37) |
| Diluted EPS | ($0.10) | ($0.13) | ($0.27) | ($0.32) | ($0.37) |
| Revenue Per Share | $0.30 | $0.28 | $0.12 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 670.7M | 666.7M | 646.0M | 570.6M | 380.8M |
| Diluted Shares Outstanding | 670.7M | 666.7M | 646.0M | 570.6M | 380.8M |
| Profitability Metrics | |||||
| EBITDA | (41.7M) | (51.9M) | (154.8M) | (174.8M) | (134.2M) |
| D&A | 865.0K | 1.2M | 1.2M | 1.0M | 868.0K |
| EBIT | (42.6M) | (53.1M) | (156.1M) | (175.8M) | (135.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026